Marinus Pharmaceuticals Under Investigation: Bragar Eagel & Squire, P.C. Represents Long-Term Stockholders and Invites Investors to Reach Out
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 27 2025
0mins
Source: Globenewswire
Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against Marinus Pharmaceuticals, Inc. (MRNS) on behalf of long-term stockholders who may have suffered losses between March 17, 2021, and May 7, 2024, following a class action complaint filed on June 5, 2024.
Legal Concerns: The lawsuit alleges that Marinus's board of directors made misleading statements regarding the risks associated with clinical trials, which may have breached their fiduciary duties to the company and its shareholders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
